A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess whether a single dose of rhBMP-2/CPM
administered at the fracture site via percutaneous injection, in combination with standard of
care, accelerates fracture union and return to normal function in subjects who have a closed
diaphyseal tibial fracture when compared to standard of care alone.